Sfrp4-flox Mouse
Common Name
Sfrp4-flox
제품 ID
S-CKO-05011
Backgroud
C57BL/6NCya
품종 계통계통 ID
CKOCMP-20379-Sfrp4-B6N-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Sfrp4-flox Mouse (카탈로그 번호 S-CKO-05011)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Sfrp4-flox
품종 계통계통 ID
CKOCMP-20379-Sfrp4-B6N-VA
유전자명
제품 ID
S-CKO-05011
유전자 별칭
--
배경
C57BL/6NCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 13
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000002883
NCBI 전사체 ID
NM_016687
타겟 영역
Exon 4
유효 영역 크기
~1.8 kb
유전자 연구 개요
Sfrp4, Secreted Frizzled Receptor Protein 4, is a decoy receptor for Wnt ligands, playing a crucial role in various biological processes. It is involved in the regulation of Wnt signaling pathways, which are essential for normal development, cell differentiation, and tissue homeostasis. Sfrp4 has significance in multiple biological systems, including the skeletal, reproductive, and cardiovascular systems, and its study using genetic models, like KO mouse models, has provided valuable insights into its functions [1-10].
In the skeletal system, Sfrp4 loss-of-function mutations cause Pyle disease, characterized by cortical bone thinning and increased fragility fractures despite increased trabecular bone density. On the endosteal surface, it represses non-canonical Wnt signaling to regulate endosteal resorption. In the periosteum, Sfrp4 is crucial for the expansion and differentiation of periosteal stem cell/progenitor cells. Sfrp4 deletion decreases the pool of Ctsk-lineage periosteal stem cells, impairs their multipotency, and hampers the periosteal response to bone injury [1,2].
In the ovary, Sfrp4-null female mice are hyperfertile due to decreased antral follicle atresia and enhanced ovulation rates. Sfrp4 promotes autophagy and blunts FSH responsiveness in ovarian granulosa cells through inhibition of AKT signaling. It also contributes to insulin-resistance-induced polycystic ovary syndrome by triggering ovarian granulosa cell hyperandrogenism and apoptosis through the nuclear β-catenin/IL-6 signaling axis [3,6,7].
In ApoE-deficient mice, overexpression of SFRP4 reduces atherosclerosis plaque formation [4]. In gastric cancer, elevated SFRP4 expression is linked to a poor prognosis and is associated with immune cell infiltration [5]. In endometrial carcinoma, PBX1 promotes SFRP4 transcription, which inhibits cell proliferation and epithelial-mesenchymal transition [8].
In conclusion, Sfrp4 is a key regulator in multiple biological processes. Studies using KO mouse models have revealed its important roles in bone development, female fertility, and disease conditions such as Pyle disease, polycystic ovary syndrome, atherosclerosis, and certain cancers. Understanding Sfrp4 functions provides potential therapeutic targets for these diseases.
References:
1. Chen, Ruiying, Baron, Roland, Gori, Francesca. 2022. Sfrp4 and the Biology of Cortical Bone. In Current osteoporosis reports, 20, 153-161. doi:10.1007/s11914-022-00727-w. https://pubmed.ncbi.nlm.nih.gov/35182301/
2. Chen, Ruiying, Dong, Han, Raval, Dhairya, Greenblatt, Matthew B, Gori, Francesca. 2023. Sfrp4 is required to maintain Ctsk-lineage periosteal stem cell niche function. In Proceedings of the National Academy of Sciences of the United States of America, 120, e2312677120. doi:10.1073/pnas.2312677120. https://pubmed.ncbi.nlm.nih.gov/37931101/
3. Bérubé, Michael, Abedini, Atefeh, Lapointe, Evelyne, Zamberlam, Gustavo, Boerboom, Derek. 2024. SFRP4 promotes autophagy and blunts FSH responsiveness through inhibition of AKT signaling in ovarian granulosa cells. In Cell communication and signaling : CCS, 22, 396. doi:10.1186/s12964-024-01736-1. https://pubmed.ncbi.nlm.nih.gov/39138534/
4. Guan, Hua, Liu, Ting, Liu, Miaomiao, Shi, Tao, Guo, Fengwei. 2023. SFRP4 Reduces Atherosclerosis Plaque Formation in ApoE Deficient Mice. In Cardiology research and practice, 2023, 8302289. doi:10.1155/2023/8302289. https://pubmed.ncbi.nlm.nih.gov/37143778/
5. Yu, Pengcheng, He, Weiyang, Zhang, Yanqiang, Cheng, Xiangdong, Xu, Zhiyuan. 2022. SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer. In Journal of oncology, 2022, 8829649. doi:10.1155/2022/8829649. https://pubmed.ncbi.nlm.nih.gov/35847366/
6. Zamberlam, Gustavo, Lapointe, Evelyne, Abedini, Atefeh, DeMayo, Francesco J, Boerboom, Derek. . SFRP4 Is a Negative Regulator of Ovarian Follicle Development and Female Fertility. In Endocrinology, 160, 1561-1572. doi:10.1210/en.2019-00212. https://pubmed.ncbi.nlm.nih.gov/30942852/
7. Wang, Jiangxia, Gui, Runlin, Li, Yang, Fan, Xiaobin, Xiong, Yuyan. 2024. SFRP4 contributes to insulin resistance-induced polycystic ovary syndrome by triggering ovarian granulosa cell hyperandrogenism and apoptosis through the nuclear β-catenin/IL-6 signaling axis. In Biochimica et biophysica acta. Molecular cell research, 1871, 119822. doi:10.1016/j.bbamcr.2024.119822. https://pubmed.ncbi.nlm.nih.gov/39159685/
8. Guo, Liwen, Chen, Huihua, Chen, Jinguo, Chen, Zichun, Cao, Luoyuan. 2023. PBX1-promoted SFRP4 transcription inhibits cell proliferation and epithelial-mesenchymal transition in endometrial carcinoma. In Tissue & cell, 82, 102083. doi:10.1016/j.tice.2023.102083. https://pubmed.ncbi.nlm.nih.gov/37054536/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
